SPRY vs ADMA

For growth investors, ADMA Biologics, Inc.

(ADMA) is the stronger pick with 19. 6% revenue growth year-over-year, versus -5. 5% for ARS Pharmaceuticals, Inc. (SPRY). ADMA Biologics, Inc. (ADMA) offers the better valuation at 14. 1x trailing P/E (9. 7x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +386. 8%, compared to -68. 0% for ARS Pharmaceuticals, Inc. (SPRY). Over 10 years, the gap is even starker: ADMA returned +34. 8% versus SPRY's -65. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ADMA Biologics, Inc.

(ADMA) is the lower-risk stock at 1. 25β versus ARS Pharmaceuticals, Inc. 's 1. 47β — meaning SPRY is approximately 17% more volatile than ADMA relative to the S&P 500.

By revenue growth (latest reported year), ADMA Biologics, Inc.

(ADMA) is pulling ahead at 19. 6% versus -5. 5% for ARS Pharmaceuticals, Inc. (SPRY). On earnings-per-share growth, the picture is similar: ADMA Biologics, Inc. grew EPS -25. 9% year-over-year, compared to -23. 3% for ARS Pharmaceuticals, Inc.. Over a 3-year CAGR, SPRY leads at 300. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus -203. 3% for ARS Pharmaceuticals, Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus -212. 9% for SPRY. At the gross margin level — before operating expenses — ADMA leads at 57. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SPRY: 183.

3% to $25. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ADMA Biologics, Inc.

(ADMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 25)). Both have compounded well over 10 years (ADMA: +34. 8%, SPRY: -65. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SPRY is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.